Fresenius Medical Care

Transcription

1 Fresenius Medical Care The World s Leading Renal Therapy Company Annual General Meeting Frankfurt am Main, May 11, 2010 Page 1

2 Agenda Accomplishments and Business Update Global Leadership Position Growth Strategy and Summary Page 2

3 Accomplishments for 2009 We achieved record results and delivered our Target Record revenue and earnings Strong organic growth in all segments Very strong cash flow development Expanded our global market share Focused on research, innovation and quality in dialysis Page 3

4 Fiscal Year 2009 Another Record Year $ in millions FY 2009 % growth Revenue 11, % at constant currency Operating Income (EBIT) 1, Net Income Page 4

5 2009 Strong Revenue Growth in all Regions Total revenue increased 6% to $11,247 m Asia-Pacific North America Revenue $639m Growth 8% cc 5% North America Revenue $7,612 m Growth actual 9% Europe Revenue $2,479m Growth 8% cc 22% 68% Growth organic 8% Euro-zone 16% Germany 3% International Revenue $3,635 m 5% Growth cc 9% Latin America Revenue $517m Growth 16% cc Growth organic 8% cc = constant currency Page 5

6 Impressive Growth Continued Revenue Net Income (in $ million) (in $ million) 12,000 11,000 10,000 9,000 8,000 7, CAGR : +14% 11,247 CAGR : +18% , , , , , Page 6

7 We Created Jobs Worldwide 3,322 +5% Location of Staff 67,988 62% North America 22% Europe 64,666 10% Latin America 6% Asia-Pacific Page 7

8 Strengthened Balance Sheet Assets Liabilities Current Assets 28% 30% 21% 17% Current Liabilities 38% 39% Non-Current Liabilities Non-Current Assets 72% 70% 41% 44% Shareholders Equity Total 14,920 15,821 14,920 15,821 in $ million Page 8

9 2009 Annual Dividend Proposal 13 th Consecutive Dividend Increase Proposed (per share in ) +5% CAGR : + 11% Long-term, profitoriented dividend policy Annual increase since foundation of the company Payout ratio in at 30% Page 9

10 Share Price Development Last 12 Months In %, indexed, May 2009 = 100 Last 12 months FME Ord. in + 44% FME Ord. in US$ + 41% DAX Index + 29% DJES Health Care + 22% Fiscal Year 2009 FME Ord. in + 11% FME Ord. in US$ + 12% DAX Index + 24% DJES Health Care + 18% Market Capitalization in uro May bn (+ 9%) May bn (+11%) Page 10

11 Strong First Quarter 2010 Clearly on track for our 2010 guidance and another record year $ in millions Q % growth Revenue 2, % at constant currency Operating Income (EBIT) Net Income Page 11

12 Agenda Accomplishments and Business Update Global Leadership Position Growth Strategy and Summary Page 12

13 Global Presence Products & Services Walnut Creek U.S. Ogden U.S. Guadalajara Mexico Reynosa Mexico L Arbresle France St. Wendel Germany Schweinfurt Germany Cremona Italy JiangSu China Buzen Japan Inukai Japan Major Production Sites HQ Dialysis Clinics North America: 1,784 clinics Latin America: 191 clinics Europe: 435 clinics Asia-Pacific: 143 clinics Page 13

14 Dialysis Services Worldwide Number of Patients Treated 2009 * FME North America 132,262 FME EMEA 32,409 DaVita 118,000 DCI 13,000 Latin America We Lead in Every Major Market, Treating more than 195,000 Patients Worldwide 18,000 12,200 # of patients # of patients FME Baxter 9,250 Diaverum 20,973 $65 Billion Market FME 6,200 3,300 7,000 KfH Diaverum Asia Pacific 10,007** Asia Renal Care Showai-Kai # of patients # of patients * Based on company statements and estimates * * 13,606 patients including managed clinics Page 14

15 Market Position Globally 1,895,000 Dialysis Patients in 2009 Dialysis patients treated in 2009 by company FME 10.3% DaVita 6.2% KfH 1.0% Diaverum 0.8% Dialysis Clinic Inc. 0.7% Baxter 0.7% Renal Advantage 0.6% Other 70% Company Owned 30% B. Braun Avitum Divers. Speciality Inst. Euromedic 0.5% 0.4% 0.4% Showai-Kai 0.4% PHV 0.3% ARC 0.3% Liberty Dialysis 0.3% ARA 0.3% Others 6.0% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% Page 15

16 Market Position by Major Product Groups Rank 1 Rank 2 Rank 3 Dialyzers FME Gambro Nipro Dialysis machines FME Gambro Nikkiso Hemodialysis concentrates FME Fuso Gambro Bloodlines FME Gambro Kawasumi Peritoneal dialysis products Baxter FME Pisa Dialyzers FMC 45% Competitors 55% Dialysis machines FMC 55% Competitors 45% Produced more than ~85,000,000 Dialyzers in 2009 Page 16

17 Agenda Accomplishments and Business Update Global Leadership Position Growth Strategy and Summary Page 17

18 Global View of Dialysis Patients Global prevalence increased by 80% over the last 10 years ESRD patients per million population (p.m.p.) Dialysis Patients 1,895,000 Hemodialysis 1,692,000 (89%) Peritoneal Dialysis 203,000 (11%) Page 18

19 Dedication to Quality Services Reduction in Mortality North America : 21% Europe : 13% Products Bloodlines Reynosa, Mexico : 85% Improvement in Quality Achieved less than 3 complaints per million while producing 73 million bloodlines per year Page 19

20 Development of Dialysis Patient Numbers 4,000,000 3,500,000 3,000,000 2,500,000 2,000, Estimates suggest an increase to greater than 3.5 million dialysis patients 1,500,000 1,000, , Renal failure persists worldwide Dialysis is the primary treatment modality on a global scale The number of global dialysis patients is expected to double by 2020 Page 20

21 Continued Growth Opportunities Therapy Integrated Care Renal Drugs 4008S 2008K Patient Care Products SleepSafe Liberty Cycler Page 21

22 Fiscal Year 2010 Outlook $ in millions Revenue > 12,000 Net income $ Capital expenditures $ Acquisitions <= $400 Strong growth expected for 2010 Page 22

23 Summary Our global presence, growth and profitability is market leading Vertical integration was and will be the best business model There are many opportunities but also challenges We will confidently continue to pursue our growth strategy, and we will remain vigilant with respect to: Quality Innovation Corporate Ethics Page 23

24 Thank You for your interest in Fresenius Medical Care! Page 24

25 Fresenius Medical Care The World s Leading Renal Therapy Company Annual General Meeting Frankfurt am Main, May 11, 2010 Page 25

26 Contacts Fresenius Medical Care AG & Co. KGaA Investor Relations Else Kröner Str Bad Homburg v.d.h. Ordinary shares WKN ISIN DE SEDOL DE Oliver Maier Head of Investor Relations & Corporate Communications Tel.: +49-(0) Fax.: +49-(0) oliver.maier@fmc-ag.com Gerrit Jost Tel.: +49-(0) Fax.: +49-(0) gerrit.jost@fmc-ag.com Terry L. Morris Tel.: Fax.: terry.morris@fmc-na.com Page 26